Genmab CEO hopes arbitration uncertainties will ease off soon
So far, Johnson & Johnson has refused Genmab around half a billion kroner (USD 76m) in a royalty dispute. Investors might be scared off until the verdict is in, says CEO Jan van de Winkel.
by MARKETWIRE, translated by daniel pedersen
Genmab is hoping that 2022 will bring an end to the arbitration dispute with the company’s partner Johnson & Johnson concerning the rights to the huge revenue inflows from cancer drug Darzalex.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab raises 2022 sales outlook to top USD 1.6bn
For subscribers
Genmab: Darzalex sales in line with expectations
For subscribers
.jpg&w=384&q=75)
